An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM)

Proteomics

Volumn 14, Issue 12, 2014, Pages 1445-1456

  Peterman, Scott ^a   Niederkofler, Eric E ^a   Phillips, David A ^a   Krastins, Bryan ^a   Kiernan, Urban A ^a   Tubbs, Kemmons A ^a   Nedelkov, Dobrin ^a   Prakash, Amol ^a   Vogelsang, Maryann S ^a   Schoeder, Tara ^a   Couchman, Lewis ^b   Taylor, David R ^b   Moniz, Cajetan F ^b   Vadali, Gouri ^a   Byram, Gregory ^a   Lopez, Mary F ^a  

^a Thermo Fisher Scientific   (United States)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetes; High resolution accurate mass; Insulin; Mass spectrometry; Targeted assay; Technology

Indexed keywords

HYPURIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; NEUTRAL INSULIN; PIG INSULIN; UNCLASSIFIED DRUG; INSULIN; ISOPROTEIN; INSULIN DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DATA EXTRACTION; DRUG BIOAVAILABILITY; HIGH THROUGHPUT SCREENING; IMMUNOASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLEXED MASS SPECTROMETRIC IMMUNOASSAY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BLOOD; HUMAN; PROCEDURES; PROTEOMICS; TANDEM MASS SPECTROMETRY; AUTOMATION; BLOOD SAMPLING; HIGH RESOLUTION AND ACCURATE MASS; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY, LIQUID; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOASSAY; INSULIN; PROTEIN ISOFORMS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84902168242     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300300     Document Type: Article

References (17)

1. Kristensen, P. L., Hansen, L. S., Jespersen, M. J., Pedersen-Bjergaard, U. et al., Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res. Clin. Pract. 2012, 96, 17-23.
2. Marks, V., Wark, G., Forensic aspects of insulin. Diabetes Res. Clin. Pract. 2013, pii: S0168-8227(13)00186-1. doi: 10.1016/j.diabres.2013.05.002.
3. Rodríguez-Cabaleiro, D., Van Uytfanghe, K., Stove, V., Fiers, T., Thienpont, L. M., Pilot study for the standardization of insulin immunoassays with isotope dilution liquid chromatography/tandem mass spectrometry. Clin. Chem. 2007, 53, 1462-1469.
4. Thevis, M., Thomas, A., Schänzer, W., Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev. 2008, 27, 35-50.
5. Oran, P. E., Jarvis, J. W., Borges, C. R., Sherma, N. D., Nelson, R. W., Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin. Appl. 2011, 5, 454-459.
6. Hess, C., Thomas, A., Thevis, M., Stratmann, B. et al., Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2012, 404, 1813-1822.
7. Chen, Z., Caulfield, M. P., McPhaul, M. J., Reitz, R. E. et al., Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin. Chem. 2013, 459, 1349-1356.
8. Lopez, M. F., Rezai, T., Sarracino, D. A., Prakash, A. et al., Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56, 281-290.
9. Krastins, B., Prakash, A., Sarracino, D. A., Nedelkov, D. et al., Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46, 399-410.
10. Manley, S. E., Stratton, I. M., Clark, P. M., Luzio, S. D., Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin. Chem. 53, 2007, 922-932.
11. Robbins, D. C., Andersen, L., Bowsher, R., Chance, R. et al., Report of the American Diabetes Association's Task Force on standardization of the insulin assay Diabetes. Diabetes 1996, 45, 242-256.
12. Owen, W. E., Roberts, W. L., Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin. Chem. 2004, 50, 257-259.
13. Heald, A. H., Bhattacharya, B., Cooper, H., Ullah, A. et al., Most commercial insulin assays fail to detect recombinant insulin analogues. Ann. Clin. Biochem. 2006, 43, 306-308.
14. Sapin, R., Le Galudec, V., Gasser, F., Pinget, M., Grucker, D., Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin. Chem. 2001, 47, 602-605.
15. Moriyama, M., Hayashi, N., Ohyabu, C., Mukai, M. et al., Performance, evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin. Chem. 2006, 52, 1423-1426.
16. Krull, I., Sahli, R., Diem, P., Stettler, C., Variability in cross-reactivity of novel insulin analogues in immunometric insulin assays. Diabet. Med. 2009, 26, 1075-1076.
17. Green, R. P., Hollander, A. S., Thevis, M., Thomas, A., Dietzen, D. J., Detection of surreptitious administration of analog insulin to an 8-week-old infant. Pediatrics 2010, 125, e1236-e1240.